^
    29d
    Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. (PubMed, Cell Rep Med)
    Additionally, activated CD8+ T cells recruit and activate neutrophils, forming a positive feedback loop. Combining trilaciclib with anti-PD-1 antibodies presents a promising strategy for NSCLC treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1) • CD177 (CD177 Molecule)
    |
    Cosela (trilaciclib)
    1m
    A Prospective Phase II Clinical Study of Trilaciclib for Preventing Myelosuppression in Patients with Locally Advanced Nasopharyngeal Carcinoma, Esophageal Carcinoma, or Cervical Carcinoma Undergoing Induction Chemotherapy Combined with Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy (ChiCTR2500110354)
    P2, N=161, Not yet recruiting, The First Affiliated Hospital, Air Force Medical University; The First Affiliated Hospital, Air Force Medical University
    New P2 trial
    |
    Cosela (trilaciclib)
    1m
    A Prospective, Multicenter, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Patients with Locally Advanced Squamous Cell Lung Cancer Receiving Concurrent Chemoradiotherapy (ChiCTR2500109840)
    P2, N=32, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    Cosela (trilaciclib)
    1m
    A prospective, single-arm, exploratory Phase II clinical study to evaluate the efficacy and safety of Trilaciclib in the first-line treatment of locally advanced cervical cancer patients with paclitaxel combined with carboplatin and radiotherapy (ChiCTR2500108685)
    P=N/A, N=30, Not yet recruiting, Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital
    New trial
    |
    carboplatin • paclitaxel • Cosela (trilaciclib)
    1m
    Efficacy and Safety of Trilaciclib in Myeloprotection during Chemotherapy for Pediatric Patients with Parameningeal Rhabdomyosarcoma with Meningeal Invasion (ChiCTR2500108628)
    P4, N=30, Not yet recruiting, Beijing Children’s Hospital, Capital Medical University; Beijing Children’s Hospital, Capital Medical University
    New P4 trial
    |
    Cosela (trilaciclib)
    2ms
    ToPCourT: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • Cosela (trilaciclib)
    2ms
    Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy (clinicaltrials.gov)
    P1/2, N=123, Completed, G1 Therapeutics, Inc. | Terminated --> Completed | Phase classification: P1b/2a --> P1/2
    Trial completion • Phase classification
    |
    topotecan • Cosela (trilaciclib)
    2ms
    Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC (clinicaltrials.gov)
    P2, N=107, Completed, G1 Therapeutics, Inc. | Terminated --> Completed
    Trial completion
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Cosela (trilaciclib)
    3ms
    The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer (clinicaltrials.gov)
    P2, N=96, Not yet recruiting, The Second Affiliated Hospital of Shandong First Medical University
    New P2 trial
    |
    albumin-bound paclitaxel • Cosela (trilaciclib)
    3ms
    Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan (clinicaltrials.gov)
    P4, N=302, Recruiting, Pharmacosmos A/S | Trial completion date: Jul 2027 --> Oct 2027 | Trial primary completion date: Jul 2027 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    topotecan • Cosela (trilaciclib)
    6ms
    PROTECT-1: Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2, N=33, Recruiting, The First Affiliated Hospital of Xiamen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Cosela (trilaciclib)
    6ms
    PROTECT-2: Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=49, Not yet recruiting, The First Affiliated Hospital of Xiamen University
    New P2 trial
    |
    Cosela (trilaciclib) • Jiataile (sacituzumab tirumotecan)